Skip Navigation

JNCI Journal of the National Cancer Institute 2008 100(11):755; doi:10.1093/jnci/djn182
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Antioxidant Supplementation During Cytotoxic Therapy

Despite extensive research, questions remain about the efficacy and safety of the use of dietary antioxidant supplementation during conventional chemotherapy and radiation therapy. Several randomized clinical trials have demonstrated that the concurrent administration of antioxidants with chemotherapy or radiation therapy reduces treatment-related side effects. However, some data indicate that antioxidants may protect tumor cells as well as healthy cells from oxidative damage from radiation or chemotherapy, although, other data suggest that antioxidants can protect normal tissues without decreasing tumor control. Lawenda et al. (p. 773) review data from preclinical . . . [Full Text of this Article]

The Role of Overlapping Tumor Supressors in Melanoma

Serum Vitamin D Level and Risk of Prostate Cancer

Trial of FEC Alone or Followed by Paclitaxel for Early Breast Cancer

ER-Dependent Signaling in an Aggressive Prostate Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?
Brian D. Lawenda, Kara M. Kelly, Elena J. Ladas, Stephen M. Sagar, Andrew Vickers, and Jeffrey B. Blumberg
J Natl Cancer Inst 2008 100: 773-783. [Abstract] [Full Text] [PDF]

Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer
Sunita R. Setlur, Kirsten D. Mertz, Yujin Hoshida, Francesca Demichelis, Mathieu Lupien, Sven Perner, Andrea Sboner, Yudi Pawitan, Ove Andrén, Laura A. Johnson, Jeff Tang, Hans-Olov Adami, Stefano Calza, Arul M. Chinnaiyan, Daniel Rhodes, Scott Tomlins, Katja Fall, Lorelei A. Mucci, Philip W. Kantoff, Meir J. Stampfer, Swen-Olof Andersson, Eberhard Varenhorst, Jan-Erik Johansson, Myles Brown, Todd R. Golub, and Mark A. Rubin
J Natl Cancer Inst 2008 100: 815-825. [Abstract] [Full Text] [PDF]

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
Miguel Martín, Álvaro Rodríguez-Lescure, Amparo Ruiz, Emilio Alba, Lourdes Calvo, Manuel Ruiz-Borrego, Blanca Munárriz, César A. Rodríguez, Carmen Crespo, Enrique de Alava, José Antonio López García-Asenjo, María Dolores Guitián, Sergio Almenar, Jesús Fernando González-Palacios, Francisco Vera, José Palacios, Manuel Ramos, Jose Manuel Gracia Marco, Ana Lluch, Isabel Alvarez, Miguel Angel Seguí, José Ignacio Mayordomo, Antonio Antón, José Manuel Baena, Arrate Plazaola, Alfonso Modolell, Amadeu Pelegrí, Jose Ramón Mel, Enrique Aranda, Encarna Adrover, José Valero Álvarez, José Luis García Puche, Pedro Sánchez-Rovira, Sonia Gonzalez, and José Manuel López-Vega On behalf of the GEICAM 9906 Study Investigators
J Natl Cancer Inst 2008 100: 805-814. [Abstract] [Full Text] [PDF]

Serum Vitamin D Concentration and Prostate Cancer Risk: A Nested Case–Control Study
Jiyoung Ahn, Ulrike Peters, Demetrius Albanes, Mark P. Purdue, Christian C. Abnet, Nilanjan Chatterjee, Ronald L. Horst, Bruce W. Hollis, Wen-Yi Huang, James M. Shikany, Richard B. Hayes, and For the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team
J Natl Cancer Inst 2008 100: 796-804. [Abstract] [Full Text] [PDF]

The Taxane Limbo: How Low Can We Go?
Clifford Hudis and Chau Dang
J Natl Cancer Inst 2008 100: 761-763. [Extract] [Full Text] [PDF]

Tumor Suppression for ARFicionados: The Relative Contributions of p16INK4a and p14ARF in Melanoma
Gordon Peters
J Natl Cancer Inst 2008 100: 757-759. [Extract] [Full Text] [PDF]

Frequent p16-Independent Inactivation of p14ARF in Human Melanoma
Daniel E. Freedberg, Sushila H. Rigas, Julie Russak, Weiming Gai, Margarita Kaplow, Iman Osman, Faye Turner, Juliette A. Randerson-Moor, Alan Houghton, Klaus Busam, D. Timothy Bishop, Boris C. Bastian, Julia A. Newton-Bishop, and David Polsky
J Natl Cancer Inst 2008 100: 784-795. [Abstract] [Full Text] [PDF]

Vitamin D and Prostate Cancer Risk—A Less Sunny Outlook?
Lorelei A. Mucci and Donna Spiegelman
J Natl Cancer Inst 2008 100: 759-761. [Extract] [Full Text] [PDF]